Articles On Genetic Signatures (ASX:GSS)

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

The ASX staged a relief rally on Monday Gold, oil stocks struggled after tensions in the Middle East eased The focus has now shifted from Middle East tensions to company earnings   The ASX put on a relief rally after its -3% loss last wee...

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported a greenlight from the TGA to sell its flu test devices on the market. At the same time, the Health Care sector is up +1.27% – suggestin...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((29M)) - 29Metals ((AX1)) - Accent Group ((AMA)) - AMA Group ((APA)) - APA Group ((LTM)) - Arcadium Lithium ((A1N)) - ARN Media ((ABB)) - Aussie Broadband ((ASB)) - Austa...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

World Overnight SPI Overnight 7046.00 – 24.00 – 0.34% S&P ASX 200 7038.20 – 38.30 – 0.54% S&P500 4273.53 – 63.91 – 1.47% Nasdaq Comp 13063.61 – 207.71 – 1.57% DJIA 33618.88 – 388.00 – 1.14% S&P500 VIX 18.94 + 2.04...

World Overnight SPI Overnight 7111.00 – 7.00 – 0.10% S&P ASX 200 7076.50 + 7.70 0.11% S&P500 4337.44 + 17.38 0.40% Nasdaq Comp 13271.32 + 59.51 0.45% DJIA 34006.88 + 43.04 0.13% S&P500 VIX 16.90 – 0.30 – 1.74% US...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

By Rudi Filapek-Vandyck, Editor FNArena Guide: The FNArena database tabulates the views of eight major Australian and international stockbrokers: Citi, Bell Potter, Macquarie, Morgan Stanley, Morgans, Ord Minnett, Shaw and Partners and UBS....

If you have a high tolerance for risk, then read on! That's because Bell Potter has just upgraded two ASX biotech shares to buy ratings this morning. Here's why the broker is feeling upbeat about these high-risk stocks: Genetic Signatures...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listedequities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArenahas now ad...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Australian molecular diagnostics company Genetic Signatures has submitted an application to the US FDA for regulatory clearance to market its EasyScreen Gastrointestinal Parasite Detection Kit.

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Genetic Signatures jumps on FDA 510(k) application Allegra says FDA has questions related to its 510(k) application Proteomics granted patent in Japan   Genetic Signatures jumps almost 20pc on FDA update There were a couple of FDA-related...

Futures indicate the ASX200 will open slightly higher as a new trading week commences, driven by growing confidence that the US Federal Reserve will pause at its next rates meeting due to the increase in unemployment in the country. In A...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Futures predict the ASX will open lower to finish the week, triggered by tech shares losing momentum on Wall Street and leading the market to also close lower. A highly anticipated speech by the US Federal Reserve chairman on the state o...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

  Dr John Melki – CEO and Director – Genetic Signatures (ASX:GSS) is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Whilst the prevalence of Artificial intelligence has boosted the US-tech sector, with the likes of Nvidia and C3.ai seeing their share prices increase by 219% and 265% respectively since the start of the year, Down Under, tech stock valuati...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Austco Healthcare wins St Paul’s Hospital in Canada worth $7.4m Next Science announced a new CEO AVITA Medical and Genetic Signatures announce new CFOs   Digital health company Austco Healthcare (ASX:AHC) surged by as high as 30% this mor...

The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley   Throughout history,...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

GSS’s share price could almost triple, according to Taylor Collison Taylor also believes Good Drinks could outperform Shaw and Partners says it has a target price on Zip that’s 4x current share price   Genetic Signatures to nearly triple...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

ShareCafeWebinar Recap – T92, GSS, ORR & SPT Catch up on the full webinar with presentations from Terra Uranium (ASX: T92), Genetic Signatures (ASX: GSS), OrecORP (ASX: ORR) & Splitit (ASX: SPT) Webinar Recap – T92, GSS, ORR &...

ShareCafeGenetic Signatures (ASX: GSS) – webinar presentation John Melki – CEO and Director – Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platfo...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

ShareCafeThe Week that Was: November 14-18, 2022 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so...

ShareCafeGenetic Signatures (ASX: GSS) – Detecting Infectious Diseases in High-Throughput Lab Workflows   Genetic Signatures Limited (ASX: GSS) CEO and Director Dr John Melki discusses the company’s technology, business model, 2022 highlig...

ASX 200 closes with -1.8% loss Small cap index down -1.2% Up way more than 100% is Norfolk Minerals, the real NFL   Everyone in this part of the world seems pretty upset by the US Federal Reserve Chairman Jerome Powell – more so than the...

As Maxwell Smart said: “Missed it by that much.” In Genetic Signatures’ (ASX:GSS) case, the close-but-no-cigar moment was its narrow June quarter loss of $169,000, which meant the company did not achieve four consecutive quarters of cash fl...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Nasdaq-listed Biogen says its experimental Alzheimer’s drug study was successful The news sends ASX-listed Cogstate to soar Orthocell could have the first FDA-approved injectable cell therapy in orthopaedics  Big news out of Nasdaq-listed...

Molecular diagnostics company Genetic Signatures (ASX:GSS) has completed recruitment for the clinical trial of its 3base EasyScreen Enteric Protozoan Diagnostic Kit in the US.

Genetic Signatures (GSS) completes recruitment for its 3base EasyScreen enteric protozoan diagnostic kit clinical trial in the US The EasyScreen enteric protozoan diagnostic kit uses GSS’ 3base technology to detect up to eight species of g...

INOVIQ reports good findings from feasibility study Mayne Pharma launches a unique oral contraceptive in the Aussie market Genetic Signatures has US FDA in its mind Diagnostics and exosome specialist INOVIQ (ASX:IIQ) – formerly called Bar...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...